Navigation Links
iCardiac Reports Significant Revenue Growth and Profitability
Date:2/23/2009

iCardiac Continues to Successfully Leverage Differentiated Service and Product Offering

Rochester, New York (PRWEB) February 23, 2009 -- iCardiac Technologies, Inc., a leading innovator in advanced cardiac safety biomakers and automated QT analysis, today announced that the company has experienced significant revenue growth as its quarter over quarter revenues have grown in excess of 100%. Pharmaceutical and biotechnology companies continue to select iCardiac as a critical provider for their cardiac safety studies because of the company's scientific expertise, project management capabilities, as well as the industry's most advanced ECG analysis methodologies, which can both dramatically reduce the cost of cardiac safety studies in addition to reducing the likelihood of false-positives. Additionally, as iCardiac's revenues have continued to increase, the company achieved profitability in the last quarter of 2008.

iCardiac continues to advance the field of cardiac safety in Phase I, II, III as well as TQT studies through its end-to-end offering of cardiac safety analysis services. During 2009, iCardiac will aggressively continue to bring to market its Highly Automated QT(sm) and QT beat-to-beat offerings.

"To date our highly automated technology has been applied in over 10 clinical QT data analyses," said Sasha Latypova, Executive Vice President at iCardiac Technologies. "Pharmaceutical companies are gaining more accurate results and are substantially lowering the cost per Thorough QT study."

The drive to greater automation of the cardiac safety analysis process stems from general dissatisfaction in the industry regarding "gold standard" manual measurements that are both time-consuming and expensive. iCardiac's highly automated QT technology is different from "fully automated" approaches - which are based solely on computers - bec
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
2. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
3. CryoLife Reports Record Annual Revenues of $105.1 Million for FY 2008
4. New Study Reports Improved Patient Outcomes for Breast Cancer Patients
5. Zogenix Reports FDA Provides New PDUFA Date for Sumavel(TM) DosePro(TM)
6. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
7. Gentiva Reports Fourth Quarter and Fiscal 2008 Results
8. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
9. Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009
10. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
11. YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... (Amex: ETC ) ("ETC" or the "Company") ... two BARA-MED(R) XD,Monoplace Hyperbaric Chambers at Christus Spohn, ... Christi, Texas, in 1905 and is,the largest and ... The,facility offers South Texans a full range of ...
... SAN DIEGO, Sept. 23 Halozyme Therapeutics,Inc. (Nasdaq: ... products targeting the extracellular matrix, today,announced that Douglas ... Vice,President, Endocrinology Clinical Development., "I am thrilled ... caliber,and achievement to the Halozyme leadership team. He ...
... Development of Novel Infectious ... Disease Diagnostic Platform -, WOBURN, ... a $4.5 million equity investment from BD (Becton, Dickinson,and Company) ... development of a novel infectious disease diagnostic,platform. The collaboration will ...
Cached Biology Technology:Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers 2Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers 3Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development 2Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development 3Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development 4U.S. Genomics Inc. Receives $4.5 Million Investment from BD 2U.S. Genomics Inc. Receives $4.5 Million Investment from BD 3
(Date:11/21/2014)... 2014   Atmel® Corporation (NASDAQ: ... touch technology solutions, today launched the industry,s first family ... widest V cc range from 1.7V to 5.5V. ... I 2 C bus communication speeds, and are available ... them ideal for consumer, industrial, computer, and medical applications. ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock Inc. ... solutions, and MorphoTrust USA (Safran), a ... today announced a strategic partnership to offer comprehensive ... vehicle administration (MVA), airport screening and financial services ... solutions, MorphoTrust serves consumers through a nationwide network ...
(Date:11/10/2014)... store shelves in early 2010, and people have used ... can be tossed into a washing machine without ever ... convenience, though, has come with risks for young children. ... Hospital found that from 2012 through 2013, U.S. poison ... 6 years of age swallowing, inhaling, or otherwise being ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Study finds laundry detergent pods, serious poisoning risk for children 2
... of ice, a minimally invasive interventional radiology treatment called ... damage, according to data being presented at the Society ... Orleans. "Cryoneurolysis could have big implications for the ... be unbearable and is very difficult to treat," said ...
... WEST ORANGE, N.J.The State of Spinal Cord Injury: Latest ... Recovery will be held on Wednesday, April 17, 2013, ... Pleasant Valley Way, West Orange, N.J. This special Grand ... Cord Injury System (NNJSCIS) and the Spinal Cord Injury ...
... have revealed the mechanism that causes a slime to ... antibiotics. When under threat, some bacteria can shield ... biofilm. It is made up of communities of bacteria ... cause dental plaque and sinusitis; in healthcare, biofilms can ...
Cached Biology News:Freezing nerves knocks pain out cold 2The State of Spinal Cord Injury Grand Rounds 2Secrets of bacterial slime revealed 2
384 Cluster Tube Racks...
The antibody recognizes the peptide sequence ESESQGPK (aa 441-448) of human class III beta-tubulin specific for neurones....
... Partially purified chicken intestinal cytoplasmic 1,25-(OH)2D3 ... receptor (VDR) from human, rat, mouse, ... This antibody does not cross-react ... MA1-710 detects both the occupied and ...
... compact, highly versatile power supply. Capable of producing ... power supply is ideal for PAGE, SDS-PAGE, DNA ... types of small format transfer apparatus. It is ... current with a continuously variable output in either ...
Biology Products: